S Leboulleux

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. doi Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 94:1310-6. 2009
  2. doi Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy
    G Hajje
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 168:113-8. 2013
  3. doi Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 164:89-94. 2011
  4. ncbi Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 93:3021-8. 2008
  5. doi Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
    D Deandreis
    Department of Nuclear Medicine and Endocrine Oncology, National Institute of Health and Medical Research, Institut Gustave Roussy, France
    Endocr Relat Cancer 18:159-69. 2011
  6. ncbi Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:920-5. 2006
  7. doi Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level
    C Nascimento
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Endocr Relat Cancer 18:R29-40. 2011
  8. ncbi Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
    C Durante
    Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:2892-9. 2006
  9. ncbi Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud XI, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Eur J Endocrinol 162:1147-53. 2010
  10. doi Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver
    D Elias
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, Cedex, France
    Eur J Surg Oncol 35:1092-7. 2009

Collaborators

Detail Information

Publications21

  1. doi Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Villejuif, France
    J Clin Endocrinol Metab 94:1310-6. 2009
    ....
  2. doi Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy
    G Hajje
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 168:113-8. 2013
    ..The aim of this study was to evaluate, in patients with advanced MTC treated with cytotoxic chemotherapy, the relationship between early changes of serum CT or CEA levels and progression-free survival (PFS)...
  3. doi Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    Eur J Endocrinol 164:89-94. 2011
    ..To make the specificity of fluorodesoxyglucose ((18)FDG) positron emission tomography (PET) precise, in the follow-up of patients with adrenal cancer...
  4. ncbi Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 93:3021-8. 2008
    ....
  5. doi Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
    D Deandreis
    Department of Nuclear Medicine and Endocrine Oncology, National Institute of Health and Medical Research, Institut Gustave Roussy, France
    Endocr Relat Cancer 18:159-69. 2011
    ..Well-differentiated thyroid cancer presenting histological features such as necrosis and FDG uptake on PET scan should be considered aggressive differentiated cancers...
  6. ncbi Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:920-5. 2006
    ....
  7. doi Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level
    C Nascimento
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Endocr Relat Cancer 18:R29-40. 2011
    ..In these patients, repeating TSH-Tg 6-18 months after ablation is not useful. (131)I ablation could be avoided in the absence of N1 and aggressive histological variant...
  8. ncbi Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
    C Durante
    Institut Gustave Roussy, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:2892-9. 2006
    ..The goal of this study was to estimate the cumulative activity of (131)I to be administered to patients with distant metastases from thyroid carcinoma...
  9. ncbi Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
    S Leboulleux
    Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, University Paris Sud XI, 39 rue Camille Desmoulins, Villejuif Cedex, France
    Eur J Endocrinol 162:1147-53. 2010
    ..Peritoneal carcinomatosis (PC) is a rare site of distant metastases in patients with adrenocortical cancer (ACC). One preliminary study suggests an increased risk of PC after laparoscopic adrenalectomy (LA) for ACC...
  10. doi Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver
    D Elias
    Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, Cedex, France
    Eur J Surg Oncol 35:1092-7. 2009
    ..It is an extensive application of the current guidelines...
  11. ncbi Chemoembolization for liver metastases from medullary thyroid carcinoma
    J Fromigue
    Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Endocrinol Metab 91:2496-9. 2006
    ..Distant metastases are the main cause of cancer-related death. Systemic chemotherapy produces only rare tumor responses. Somatostatin analogs and other available modalities are poorly effective to control symptoms...
  12. doi Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Univ Paris Sud, Villejuif, France
    Horm Cancer 2:363-71. 2011
    ..International networks and comprehensive databases gathering clinical and biological data constitute the prerequisites for progress...
  13. pmc Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging
    G Pellegriti
    , Institut Gustave Roussy, Villejuif, France
    Br J Cancer 88:1537-42. 2003
    ..01). These results show that postoperative CT level and tumour extension are critical prognostic factors for the identification of patients at a high risk of relapse...
  14. pmc Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon
    A Boichard
    Institut Gustave Roussy, Translational Research Laboratory, 114 rue Edouard Vaillant, 94805 Villejuif, France
    J Clin Endocrinol Metab 97:E2031-5. 2012
    ..Recently, a high prevalence of RAS mutations was reported in sporadic MTC, suggesting an alternative genetic event in sporadic MTC tumorigenesis...
  15. doi [Outcome of cervical carcinoma with locoregional lymph node involvement by FDG-PET]
    A Paumier
    Departement de Radiotherapie, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Cancer Radiother 16:183-9. 2012
    ..To assess the outcome of cervical carcinoma with positive nodes on fluorodesoxyglucose positon emission tomography scans (FDG-PET)...
  16. ncbi Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients
    E Baudin
    Department of Nuclear Medicine and Endocrine Tumors, Institut Gustave Roussy, Villejuif, France 94805
    J Clin Endocrinol Metab 88:1107-11. 2003
    ..The best PPV is brought by the slope of serum Tg levels...
  17. doi [The accuracy of FDG-PET/CT in early-stage cervical and vaginal cancers]
    E Bentivegna
    Departement de Chirurgie, Institut Gustave Roussy, Universite Paris Sud, Villejuif, France
    Gynecol Obstet Fertil 39:193-7. 2011
    ..The aim of this study was to evaluate false negative rate of FDG-PET/CT in early-stage cervical and vaginal cancer...
  18. doi Molecular targeted therapies for patients with refractory thyroid cancer
    C Chougnet
    Department of Nuclear Medicine and Endocrine Oncology, Centre de Référence Tumeurs Réfractaires de la Thyroïde, Institut Gustave Roussy and University Paris Sud XI, Villejuif, France
    Clin Oncol (R Coll Radiol) 22:448-55. 2010
    ..In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial...
  19. ncbi A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas
    M P Ducreux
    Gastroenterology Unit, Institute Gustave Roussy, Villejuif, France
    Oncology 70:134-40. 2006
    ..Only a few drugs are active in the treatment of well-differentiated endocrine carcinomas (WDEC). We evaluated the combination of the so-called 'de Gramont schedule' and irinotecan in these tumors in a phase II study...
  20. ncbi Myasthenia gravis mimicking unilateral vocal fold paralysis at presentation
    D M Hartl
    Otolaryngology and Head and Neck Surgery, Institute Gustave Roussy, Villejuif, France
    J Laryngol Otol 121:174-8. 2007
    ..To demonstrate the importance of detailed clinical analysis in the differential diagnosis of unilateral vocal fold paralysis, and to provide an update on current knowledge and treatment of myasthenia gravis...
  21. ncbi Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course
    S Leboulleux
    Service de Cancérologie Endocrinienne et de Médecine Nucléaire, Institut Gustave Roussy, Villejuif, France
    Cancer 94:44-50. 2002
    ..Multiple endocrine neoplasia type 2B (MEN 2B) is an exceptional syndrome, for which the optimal age of thyroidectomy is poorly established and the course of medullary thyroid carcinoma (MTC) is ill-defined...